- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.10. | Molecure inks $32 million deal with Ocean Biomedical for cancer therapy | 2 | Investing.com | ||
| 15.10. | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 135 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
| 01.08. | Molecure and Avicenna link to develop cancer drugs | 1 | Pharmaceutical Technology | ||
| 31.07. | Avicenna Biosciences, Inc.: Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs | 356 | Business Wire | Molecure S.A. ('Molecure', SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development... ► Artikel lesen | |
| 21.05. | Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway | 162 | GlobeNewswire (Europe) | OATD-01 is a first-in-class chitotriosidase 1 (CHIT1) inhibitor with the potential to modify the course of disease in sarcoidosis and other interstitial lung diseases.Obtaining regulatory approvals... ► Artikel lesen | |
| 03.04. | Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025 | 191 | GlobeNewswire (Europe) | Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare... ► Artikel lesen | |
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 22.03. | Molecure: First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis | 119 | GlobeNewswire (Europe) | - OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase... ► Artikel lesen | |
| 19.12.23 | Molecure - Progressing the validation of mRNA platform | 429 | Edison Investment Research | Molecure has announced that it has generated the in vitro proof-of-concept (PoC) data for its mRNA platform, marking a step toward one of its long-term strategic objectives. Based on an in vitro study... ► Artikel lesen |
8 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANGAMO THERAPEUTICS | 1,905 | +2,67 % | Sangamo stock climbs 12% post-market on FDA update for ST-503 | ||
| IMMATICS | 7,510 | +1,42 % | Immatics: Deutsche Biotech-Hoffnung unter Druck | Trotz vielversprechender Studiendaten befindet sich der Biotech-Hot-Stock Immatics sei einigen Wochen auf dem absteigenden Ast. Vor allem das Timing einer Kapitalmaßnahme ist einigen Marktteilnehmern... ► Artikel lesen | |
| ALDEYRA | 4,510 | -0,04 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases,... ► Artikel lesen | |
| MEDIFAST | 16,840 | -2,38 % | How Should You Play Medifast Stock at a P/E Multiple of 17.6X? | ||
| PHARMING | 0,695 | -3,34 % | Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy | Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH 29.10.2024 / 14:51 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG. The issuer... ► Artikel lesen | |
| COHERUS | 0,926 | -11,66 % | Coherus BioSciences, Inc.: Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update | - Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter - - UDENYCA labeling and packaging production resuming at third-party contract manufacturing... ► Artikel lesen | |
| ORUKA THERAPEUTICS | 20,800 | 0,00 % | Oruka Therapeutics, Inc. - 8-K, Current Report | ||
| INNOVIVA | 18,000 | -0,55 % | Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress | BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 1,820 | 0,00 % | Armata Pharmaceuticals, Inc. - 8-K, Current Report | ||
| SIGA TECHNOLOGIES | 6,250 | 0,00 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 2,200 | 0,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update | Conference call planned for later in Q4 2024 to provide updates on NurOwn® program
NEW YORK, Nov. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc.... ► Artikel lesen | |
| DBV TECHNOLOGIES | 0,521 | +0,77 % | DBVT stock touches 52-week low at $0.47 amid market challenges | ||
| MATINAS BIOPHARMA | 0,572 | 0,00 % | Matinas BioPharma Holdings, Inc.: Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction | BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding... ► Artikel lesen | |
| LIQUIDIA | 9,500 | -1,04 % | The Analyst Landscape: 11 Takes On Liquidia | ||
| SYNDAX PHARMACEUTICALS | 14,300 | 0,00 % | Syndax Pharmaceuticals, Inc.: Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation | - Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients... ► Artikel lesen |
MOLECURE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +15,45 % bei einem Aktienkurs von 2,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.
